用α-硫辛酸治疗可降低 2 型糖尿病患者的不对称二甲基精氨酸。
Treatment with alpha-lipoic acid reduces asymmetric dimethylarginine in patients with type 2 diabetes mellitus.
机构信息
Department of Clinical Pharmacology, Medical University Vienna, Vienna, Austria.
出版信息
Transl Res. 2010 Jan;155(1):6-9. doi: 10.1016/j.trsl.2009.08.004.
Elevated asymmetric dimethylarginine (ADMA) concentrations predict cardiovascular events in patients with type 2 diabetes mellitus (T2DM). It has been shown that alpha-lipoic acid (ALA) improves endothelial function and oxidative stress in these patients. The present study investigated if ALA reduces ADMA in patients with T2DM. Plasma concentrations of ADMA, L-arginine and symmetric dimethylarginine (SDMA) were determined in a double-blind, randomized, placebo-controlled study in patients with T2DM. Intravenous ALA (n = 16) or placebo (n = 14) was administered daily for 3 weeks. ALA reduced ADMA while no change was observed with placebo (mean change -0.05 micromol/1[95% CI: -0.01; -0.09] vs. 0.01 micromol/1 [95% CI: -0.05; -0.03]; ANOVA p = 0.031). SDMA and L-arginine were not affected by ALA. In conclusion ALA treatment reduces ADMA in patients with T2DM. Long-term studies need to demonstrate if ALA may cause cardiovascular risk reduction.
血浆不对称二甲基精氨酸（ADMA）浓度升高可预测 2 型糖尿病（T2DM）患者的心血管事件。已有研究表明，α-硫辛酸（ALA）可改善此类患者的内皮功能和氧化应激。本研究旨在探讨 ALA 是否可降低 T2DM 患者的 ADMA 水平。在一项 T2DM 患者的双盲、随机、安慰剂对照研究中，测定了 ADMA、L-精氨酸和对称二甲基精氨酸（SDMA）的血浆浓度。T2DM 患者每日静脉内给予 ALA（n = 16）或安慰剂（n = 14），连续 3 周。ALA 可降低 ADMA，而安慰剂组无变化（平均变化-0.05 μmol/1[95%CI：-0.01；-0.09]与 0.01 μmol/1[95%CI：-0.05；-0.03]；ANOVA p = 0.031）。ALA 对 SDMA 和 L-精氨酸无影响。结论：ALA 治疗可降低 T2DM 患者的 ADMA 水平。需要进行长期研究以证实 ALA 是否可降低心血管风险。
Zotero 插件